Pharmaceutical

UK’s pricing watchdog rejects Alzheimer treatments for the second time

NICE previously rejected Leqembi and Kisunla for NHS coverage in August and October 2024, respectively.

Mar 9, 2025 - 06:00
UK’s pricing watchdog rejects Alzheimer treatments for the second time
NICE previously rejected Leqembi and Kisunla for NHS coverage in August and October 2024, respectively.
Read the original article

Tags:

Previous Article

Post-LLM Revolution: Exploring New Frontiers in AI Through Knowledge, Collaborat...

Next Article

J&J drops Phase III MDD programme due to lack of efficacy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Australia lists new medicines for GVHD and chronic rhinosinusitis

Australia lists new medicines for GVHD and chronic rhin...

Apr 10, 2023

STAT+: With Biden finalizing an Apple Watch ban, Apple needs to decide its future in health

STAT+: With Biden finalizing an Apple Watch ban, Apple ...

Dec 27, 2023

STAT+: Pharmalittle: FDA slams company recalling eye drops over manufacturing issues; U.S. funds massive Alzheimer’s research database

STAT+: Pharmalittle: FDA slams company recalling eye dr...

Apr 3, 2023